Exosomes Derived from Human Amniotic Fluid Mesenchymal Stem Cells Preserve Microglia and Neuron Cells from Aβ.
Alzheimer
exosomes
neuroinflammation
stem cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 Apr 2022
29 Apr 2022
Historique:
received:
04
04
2022
revised:
26
04
2022
accepted:
28
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
18
5
2022
Statut:
epublish
Résumé
Neuroinflammation is involved in neuronal cell death that occurs in neurodegenerative diseases such as Alzheimer's disease (AD). Microglia play important roles in regulating the brain amyloid beta (Aβ) levels, so immunomodulatory properties exerted by mesenchymal stem cells may be exploited to treat this pathology. The evidence suggests that the mechanism of action of human amniotic fluid stem cells (hAFSCs) is through their secretome, which includes exosomes (exo). We examined the effect of exosomes derived from human amniotic fluid stem cells (hAFSCs-exo) on activated BV-2 microglia cells by lipopolysaccharide (LPS) as a neuroinflammation model. To investigate the exo effect on the interplay between AD neurons and microglia, SH-SY5Y neuroblastoma cells treated with Aβ were exposed to a conditioned medium (CM) obtained from activated BV-2 or co-culture systems. We found that the upregulation of the markers of pro-inflammatory microglia was prevented when exposed to hAFSC-exo whereas the markers of the anti-inflammatory macrophage phenotype were not affected. Interestingly, the hAFSC-exo pretreatment significantly inhibited the oxidative stress rise and apoptosis occurring in the neurons in presence of both microglia and Aβ. We demonstrated that hAFSC-exo mitigated an inflammatory injury caused by microglia and significantly recovered the neurotoxicity, suggesting that hAFSC-exo may be a potential therapeutic agent for inflammation-related neurological conditions, including AD.
Sections du résumé
BACKGROUND
BACKGROUND
Neuroinflammation is involved in neuronal cell death that occurs in neurodegenerative diseases such as Alzheimer's disease (AD). Microglia play important roles in regulating the brain amyloid beta (Aβ) levels, so immunomodulatory properties exerted by mesenchymal stem cells may be exploited to treat this pathology. The evidence suggests that the mechanism of action of human amniotic fluid stem cells (hAFSCs) is through their secretome, which includes exosomes (exo).
METHODS
METHODS
We examined the effect of exosomes derived from human amniotic fluid stem cells (hAFSCs-exo) on activated BV-2 microglia cells by lipopolysaccharide (LPS) as a neuroinflammation model. To investigate the exo effect on the interplay between AD neurons and microglia, SH-SY5Y neuroblastoma cells treated with Aβ were exposed to a conditioned medium (CM) obtained from activated BV-2 or co-culture systems.
RESULTS
RESULTS
We found that the upregulation of the markers of pro-inflammatory microglia was prevented when exposed to hAFSC-exo whereas the markers of the anti-inflammatory macrophage phenotype were not affected. Interestingly, the hAFSC-exo pretreatment significantly inhibited the oxidative stress rise and apoptosis occurring in the neurons in presence of both microglia and Aβ.
CONCLUSION
CONCLUSIONS
We demonstrated that hAFSC-exo mitigated an inflammatory injury caused by microglia and significantly recovered the neurotoxicity, suggesting that hAFSC-exo may be a potential therapeutic agent for inflammation-related neurological conditions, including AD.
Identifiants
pubmed: 35563358
pii: ijms23094967
doi: 10.3390/ijms23094967
pmc: PMC9105787
pii:
doi:
Substances chimiques
Amyloid beta-Peptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : University of Modena and Reggio Emilia
ID : FAR 2021
Références
J Neural Transm (Vienna). 2010 Aug;117(8):949-60
pubmed: 20552234
Neurochem Res. 2018 Nov;43(11):2165-2177
pubmed: 30259257
Front Neurol. 2019 Nov 29;10:1225
pubmed: 31849808
Biomed Res Int. 2014;2014:456937
pubmed: 24719867
Biofactors. 2020 Jan;46(1):106-117
pubmed: 31625201
Mini Rev Med Chem. 2021;21(4):520-534
pubmed: 31198113
Neuron. 2016 Jul 20;91(2):328-40
pubmed: 27477018
Exp Cell Res. 2010 Oct 15;316(17):2961-8
pubmed: 20620137
Stem Cells Int. 2018 Jul 29;2018:6126413
pubmed: 30151012
Nat Neurosci. 2020 Aug;23(8):927-938
pubmed: 32514138
Stem Cell Res Ther. 2019 Mar 21;10(1):105
pubmed: 30898154
Front Bioeng Biotechnol. 2021 Feb 05;9:637737
pubmed: 33614619
Aging Med (Milton). 2019 May 31;2(2):88-93
pubmed: 31942517
Immunity. 2020 Feb 18;52(2):222-240
pubmed: 31924476
Biomed Res Int. 2018 Mar 8;2018:3740461
pubmed: 29707568
Eur J Neurol. 2018 Jan;25(1):59-70
pubmed: 28872215
Neurochem Res. 2013 Sep 29;:
pubmed: 24078266
Oxid Med Cell Longev. 2015;2015:101304
pubmed: 26273418
Molecules. 2019 Apr 22;24(8):
pubmed: 31013638
Redox Biol. 2016 Aug;8:205-15
pubmed: 26820564
Cell Death Discov. 2021 May 10;7(1):98
pubmed: 33972507
Oxid Med Cell Longev. 2017;2017:3724545
pubmed: 28947927
Biochim Biophys Acta. 2014 Aug;1842(8):1240-7
pubmed: 24189435
Biofactors. 2004;20(4):223-33
pubmed: 15706059
Life Sci. 2015 Jan 15;121:174-83
pubmed: 25445219
Oxid Med Cell Longev. 2013;2013:680816
pubmed: 24489986
Mech Ageing Dev. 2021 Apr;195:111438
pubmed: 33516818
J Alzheimers Dis. 2019;72(3):867-884
pubmed: 31640102
Biofactors. 2018 Mar;44(2):158-167
pubmed: 29341292
Oxid Med Cell Longev. 2020 Oct 24;2020:2785343
pubmed: 33193997
Nat Rev Neurosci. 2018 Oct;19(10):622-635
pubmed: 30206328
Stem Cell Res Ther. 2019 Nov 20;10(1):332
pubmed: 31747944
Sci Rep. 2018 Jan 10;8(1):354
pubmed: 29321508
Alzheimers Res Ther. 2021 Sep 14;13(1):154
pubmed: 34521461
Sci Rep. 2013;3:1197
pubmed: 23378928
Trends Immunol. 2020 Sep;41(9):836-848
pubmed: 32741652